This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income
(NYSE: ABBV) is a large drug company with a somewhat unusual portfolio of products, spanning immunology (Skyrizi and Rinvoq) to esthetics (Botox). However, for many investors, the big draw is going to be the dividend. With a currently high yield and strong cash flow, AbbVie could provide dividend lovers with reliable income for years to come.
The S 500 index has a paltry yield of 1.1% today. The average pharmaceutical company, using iShares U.S. Pharmaceuticals ETF as an industry proxy, yields 1.7%. AbbVie's dividend yield is now 2.9%.
Image source: Getty Images.
Source Fool.com
AbbVie Inc. Stock
€177.60
-0.420%
With 32 Buy predictions and not a single Sell prediction AbbVie Inc. is an absolute favorite of our community.
With a target price of 209 € there is a slightly positive potential of 17.68% for AbbVie Inc. compared to the current price of 177.6 €.
